Last checked at 
LONDON (Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:----------FTSE 100----------GOLDMAN CUTS BURBERRY GROUP TO 'NEUTRAL' ('CONVICTION BUY LIST') - TARGET 2536 PENCE----------RBC RAISES BURBERRY GROUP PRICE TARGET TO 1875 (1750) PENCE - 'UNDERPERFORM'----------RBC INITIATES DCC WITH 'OUTPERFORM' - TARGET 9500 PENCE----------RBC CUTS BUNZL PRICE TARGET TO 1800 (1950) PENCE - 'UNDERPERFORM'----------BERENBERG CUTS SHIRE TO 'HOLD' ('BUY') - TARGET 5000 (4500) PENCE----------JPMORGAN RAISES MELROSE INDUSTRIES PRICE TARGET TO 285 (260) PENCE - 'OVERWEIGHT'----------REDBURN CUTS HSBC TO 'SELL' ('NEUTRAL')----------BARCLAYS RAISES ST JAMES'S PLACE PRICE TARGET TO 1456 (1387) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES RSA INSURANCE PRICE TARGET TO 696 (693) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES PRUDENTIAL PRICE TARGET TO 2163 (2076) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES LEGAL & GENERAL GROUP PRICE TARGET TO 317 (311) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES DIRECT LINE PRICE TARGET TO 366 (361) PENCE - 'EQUAL WEIGHT'----------BARCLAYS RAISES AVIVA PRICE TARGET TO 610 (581) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES ADMIRAL GROUP PRICE TARGET TO 1997 (1939) PENCE - 'UNDERWEIGHT'----------HSBC RAISES CENTRICA PRICE TARGET TO 142 (130) PENCE - 'REDUCE'----------KEPLER CHEUVREUX RAISES ASTRAZENECA PRICE TARGET TO 6100 (5630) PENCE - 'BUY'----------JEFFERIES CUTS ASTRAZENECA PRICE TARGET TO 5975 (6200) PENCE - 'HOLD'----------JEFFERIES CUTS GLAXOSMITHKLINE PRICE TARGET TO 1725 (1775) PENCE - 'BUY'----------FTSE 250----------JPMORGAN CUTS GO-AHEAD GROUP PRICE TARGET TO 1420 (1421) PENCE - 'UNDERWEIGHT'----------JPMORGAN CUTS WEIR GROUP PRICE TARGET TO 2060 (2200) PENCE - 'OVERWEIGHT'----------BARCLAYS CUTS WEIR GROUP PRICE TARGET TO 2500 (2600) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES PHOENIX GROUP PRICE TARGET TO 688 (667) PENCE - 'UNDERWEIGHT'----------BARCLAYS RAISES LANCASHIRE HOLDINGS PRICE TARGET TO 693 (667) PENCE - 'EQUAL WEIGHT'----------BARCLAYS RAISES JARDINE LLOYD THOMPSON PRICE TARGET TO 1523 (1495) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES HISCOX PRICE TARGET TO 1427 (1314) PENCE - 'UNDERWEIGHT'----------BARCLAYS RAISES HASTINGS GROUP PRICE TARGET TO 272 (267) PENCE - 'EQUAL WEIGHT'----------PEEL HUNT RAISES GREENE KING TO 'BUY' ('ADD') - TARGET 700 PENCE----------KEPLER CHEUVREUX RAISES GENUS PRICE TARGET TO 2540 (2470) PENCE - 'HOLD'----------CREDIT SUISSE CUTS WILLIAM HILL PRICE TARGET TO 330 (340) PENCE - 'OUTPERFORM'----------HSBC CUTS WILLIAM HILL PRICE TARGET TO 290 (325) PENCE - 'HOLD'----------OTHER MAIN MARKET AND AIM----------BERENBERG INITIATES GLOBALDATA WITH 'BUY' - TARGET 820 PENCE----------JPMORGAN RAISES REDDE PRICE TARGET TO 207 (197) PENCE - 'OVERWEIGHT'----------PEEL HUNT RESUMES CHEMRING GROUP WITH 'ADD' - TARGET 240 PENCE----------PEEL HUNT RESUMES PAN AFRICAN RESOURCES WITH 'BUY' - TARGET 16 PENCE----------LIBERUM PUTS EI GROUP RATING UNDER REVIEW FROM 'HOLD'----------
21 Feb 2024 07:22
GSK's ViiV sees success in latest HIV treatment trial
(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.
Read more